RPX-101A

RPX-101A is a preclinical-stage small molecule inhibitor of **soluble epoxide hydrolase (sEH)** being developed by **Repoxegen Therapeutics**. The drug is designed to treat a variety of neurodegenerative and ophthalmic conditions by modulating the metabolism of epoxyeicosatrienoic acids (EETs), which possess anti-inflammatory, anti-apoptotic, and neuroprotective properties. By inhibiting sEH, RPX-101A aims to stabilize EET levels, thereby reducing neuroinflammation and vascular leakage. Its primary indications include diabetic retinopathy, age-related macular degeneration (AMD), glaucoma, and macular edema, as well as neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and progressive supranuclear palsy (PSP).

Other names

RPX-101ARPX101ARPX 101A